Stanford study finds low risk of secondary blood cancers after CAR-T cell therapy

  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 88 sec. here
  • 24 min. at publisher
  • 📊 Quality Score:
  • News: 111%
  • Publisher: 71%

Cell News

Medicine,Antigen,Blood

A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy -; a cell-based cancer treatment that exploded on the scene in 2017 as a treatment for intractable blood cancers -; is low, despite a Food and Drug Administration warning.

Jun 12 2024Stanford Medicine A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy -; a cell-based cancer treatment that exploded on the scene in 2017 as a treatment for intractable blood cancers -; is low, despite a Food and Drug Administration warning.

We wanted to understand this one rare case, so we analyzed all the patients treated with CAR-T cell therapy at Stanford with wide breadth and studied this single case extraordinary depth. We compared protein levels, RNA sequences and DNA from single cells across multiple tissues and time points to determine that the therapy didn't introduce the lymphoma into this patient; instead it was already brewing in their body at very low levels.

In CAR-T cell therapy, immune cells called T cells are isolated from a patient and genetically engineered to more efficiently seek out and kill cancer cells. To do so, researchers introduce a custom-made gene into the T cells' DNA. This gene encodes instructions for a protein called a chimeric antigen receptor that recognizes and binds to cancer cells; when the protein is made by the T cells and affixed to their surfaces, they become efficient cancer-killing machines.

The researchers analyzed the outcomes for 724 people treated with CAR-T cell therapy at Stanford Health Care between 2016 and 2024. Among those people, the incidence of secondary blood cancers approached 6.5% over a median of three years of follow-up, which is roughly similar to patients who underwent stem cell transplantation rather than CAR-T cell therapy to treat their cancers.

The analysis found no evidence that the T cells responsible for the patient's second cancer were the T cells engineered for the CAR-T cell therapy -; they were molecularly and genetically distinct. However, both sets of T cells were infected with a virus known to play a role in cancer development. Furthermore, the patient had a history of autoimmune disease in the years prior to their first cancer diagnosis.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 19. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeuticClosed Loop Medicine Ltd, a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, and Pharmanovia, a global pharmaceutical company that commercializes novel medicines and revitalizes, extends and expands the lifecycle of established medicines, today announced...
Source: NewsMedical - 🏆 19. / 71 Read more »